Nature5 年
Low NT-proBNP levels can rule out ventricular dysfunction in patients with CHD
The inactive N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) has been linked to ventricular dysfunction in the general population, and is predictive of cardiac events. Corteville ...
Medscape4 天
Diagnostic Accuracy of Point-of-care Testing for Acute Coronary Syndromes, Heart Failure ...
Our results emphasise the clinical value of POCT using a novel cardiovascular marker device measuring cTnT, NT-proBNP and D-dimer for the risk stratification of ACS, HF and TE in primary care.
Managed Healthcare Executive7 天
FDA Approves Attruby for Heart Failure Indication
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
GlobalData on MSN7 天
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
Medpage Today on MSN15 天
Novel CRISPR-Cas9-Based Promising in ATTR Cardiomyopathy
A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...